Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $10.00

Aveanna Healthcare (NASDAQ:AVAH) had its target price hoisted by UBS Group from $9.50 to $10.00 in a research note issued to investors on Thursday morning,Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other research firms have also issued reports on AVAH. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Monday, December 29th. Truist Financial increased their target price on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a “hold” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. upgraded Aveanna Healthcare from an “underweight” rating to a “neutral” rating and boosted their price target for the company from $6.00 to $10.00 in a research note on Thursday, September 18th. BMO Capital Markets initiated coverage on Aveanna Healthcare in a report on Thursday, November 13th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Zacks Research downgraded Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 20th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $11.06.

Aveanna Healthcare Stock Performance

Shares of NASDAQ AVAH opened at $9.22 on Thursday. Aveanna Healthcare has a 12 month low of $3.67 and a 12 month high of $10.32. The company has a market cap of $1.93 billion, a P/E ratio of 25.61 and a beta of 2.06. The business’s 50 day moving average is $8.83 and its two-hundred day moving average is $7.78. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39.

Aveanna Healthcare (NASDAQ:AVAH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.08. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. The business had revenue of $621.94 million for the quarter, compared to the consensus estimate of $578.57 million. On average, equities analysts expect that Aveanna Healthcare will post -0.06 EPS for the current year.

Insider Buying and Selling at Aveanna Healthcare

In related news, CEO Jeff Shaner sold 29,357 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $7.85, for a total value of $230,452.45. Following the sale, the chief executive officer owned 2,394,179 shares of the company’s stock, valued at $18,794,305.15. The trade was a 1.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Robert M. Williams, Jr. sold 10,000,000 shares of the company’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $9.00, for a total value of $90,000,000.00. Following the completion of the sale, the insider owned 386,284 shares in the company, valued at $3,476,556. This trade represents a 96.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,857,606 shares of company stock worth $295,491,307 over the last three months. 7.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aveanna Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in Aveanna Healthcare by 21.2% during the first quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock worth $142,000 after buying an additional 4,602 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Aveanna Healthcare by 8.3% in the first quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock valued at $1,842,000 after acquiring an additional 25,974 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Aveanna Healthcare by 522.0% in the 1st quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock worth $407,000 after acquiring an additional 63,010 shares in the last quarter. Strs Ohio bought a new stake in Aveanna Healthcare during the 1st quarter worth approximately $218,000. Finally, Rhumbline Advisers increased its holdings in Aveanna Healthcare by 4.0% during the 1st quarter. Rhumbline Advisers now owns 75,581 shares of the company’s stock valued at $410,000 after purchasing an additional 2,918 shares in the last quarter. 87.96% of the stock is currently owned by institutional investors and hedge funds.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.